Welcome

Welcome to Market Newsdesk! For access to published news releases, please browse below, head to our News Articles page, or use the Search function. To watch the news wires in real time, start our Real Time News app from the menu above (Chrome, Safari, or Edge browsers recommended), and click Connect. Then click on any headline to read the full article. You can also filter the incoming news by entering a Ticker symbol in the filter. Enjoy!

Articles

2020 VLSI-TSA and VLSI-DAT Symposia will Kick Off on April 20

Focusing on 5G, AI, Robotics, Quantum Computing and Bioelectronic Medicine HSINCHU, Taiwan, Dec. 13, 2019 (GLOBE NEWSWIRE) — AI, 5G, Robotics, Quantum Computing and Bioelectronic Medicine are bringing about changes in the semiconductor industry. To address these trends, the Industrial Technology Research Institute (ITRI) will host the 2020 International Symposia on VLSI Technology, Systems and Applications (VLSI-TSA) and Design, Automation and Test (VLSI-DAT) during April 20-23, 2020 in Hsinchu, Taiwan. Experts from top companies and academic institutions, including Intel, IBM, MIT, UCLA, Eidgenössische Technische Hochschule Zürich and Eridan Communications will share their experiences and research findings on the latest updates in AI, 5G, Robotics, Quantum Computing, Bioelectronic Medicine and advanced silicon and assembly process technologies.  The VLSI-TSA and VLSI-DAT symposia, first …

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF V600 mutation-positive advanced melanoma. Genentech, Inc. (a member of the Roche Group), Exelixis’ collaborator and the sponsor of the IMspire150 trial, informed the company that the study met its primary endpoint of progression-free survival (PFS). Adding atezolizumab to cobimetinib and vemurafenib helped to reduce the risk of disease worsening or death, compared to placebo plus cobimetinib and vemurafenib. A significant and clinically meaningful …

Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

MARSEILLE, France, Dec. 13, 2019 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102, a potentially first-in-class anti-KIR3DL2 antibody). The Company will take the following actions based on ongoing discussions with regulatory authorities regarding a quality issue related to the chemistry, manufacturing and controls (CMC) process: Lacutamab will not be administered to new patients in the TELLOMAK trial until additional feedback is received from the respective regulatory agencies overseeing our clinical trial. Until further notice, the Company will continue to treat patients who are currently enrolled in the multi-center trial, except in Italy where the …